Boehringer Ingelheim Investigational Site

Kansas City, Kansas

0 studies enrolling now · 1 studies all time

What they study most

Parkinson Disease

Studies at this site

• A Fourteen-Week Placebo-Controlled Dose-Response Efficacy and Safety Study of NS 2330 in Early Parkinson's Disease Patients (Study for Proof of Concept in Early Parkinson's Disease of a Triple Reuptake Inhibitor, NS 2330 / SCEPTRE) — Completed